Business Description
Founded in 2020 and headquartered in Cambridge, Massachusetts, with operations in Denmark, Hemab Therapeutics is an early-stage medical company focused on developing new treatments for rare bleeding disorders. Its lead medicine, HMB-001, is currently being tested in clinical trials for two conditions that prevent blood from clotting properly, while a second treatment, HMB-002, targets Von Willebrand disease, another disorder that impairs the body's ability to stop bleeding. The company is also working on several additional treatments in earlier stages of research.
